WillItSurvive
No grouping · Malaysia

Powercheck AI Holdings Limited

Pre-revenue Malaysian AI health-screening startup filing to list on Nasdaq as PCAI.

Little protection left
Assessed 29 July 2026 · Evidence as of 29 July 2026
Not much stands between this business and its pressures.
On the recordSince 29 July 2026 · Checkable from TBD 2026 · Every call on the record Checkpoint: Nasdaq IPO pricing and listing date for PCAI
The call

A pre-revenue health-screening idea filing for a small Nasdaq listing while larger, funded rivals already sell similar screening through established retail and hospital channels.

Powercheck AI Holdings wants to use artificial intelligence to read health screening tests and help people understand their results, but the company is in trouble before it even gets started. Bigger companies like Prenetics (which owns CircleDNA) already sell health screenings through pharmacy chains, and tech giants like NVIDIA and Illumina are building their own AI systems to read genetic tests, meaning Powercheck's core technology is not unique and is getting easier to copy every day. The only thing that could matter is whether Powercheck actually opens physical clinics in Malaysia that people prefer to visit, gets major hospitals or employers to sign contracts with it after going public, and raises enough money to stay alive while it builds that out, but right now it has almost no money and no clinics yet.

Why
01
AI pressure: NVIDIA-backed genomics AI and Illumina bioinformatics platforms. Big AI-genomics infrastructure already reads and interprets genetic data at scale, the exact layer Powercheck plans to build. Could AI do the core job? Yes, likely.
02
Bigger players: Prenetics/CircleDNA (Nasdaq: PRE), distributed through Watsons retail. CircleDNA already sells consumer genetic and health screening through thousands of Watsons stores across the region Powercheck wants to enter. Could a giant copy it? Yes, easily.
03
What protects it. None concrete yet: planned Kuala Lumpur and Penang clinics are the only local asset, and they are unbuilt.
What would change this call
Whether PCAI's Nasdaq listing actually prices and closes within 2026. Shows if the company can even fund operations before facing Prenetics/CircleDNA in market.
Any signed hospital, insurer, or corporate wellness contract announced in Malaysia within 6 months of listing. Would show first real commercial traction rather than pre-revenue status.
Progress on opening physical clinics in Kuala Lumpur or Penang. Tests whether its only potentially uncopied asset gets built or stays vaporware.
Key numbers
  • FY2025 revenue: $1,865 (2026-06-15)
  • Cash on hand: $28,075 (2026-06-15)
  • Total debt: $104,548 (2026-06-15)
Named risks
  • Pre-commercial with FY2025 revenue of only $1,865 and no disclosed institutional customers. Severity: high
  • Core AI-interpretation layer is the exact workflow being commoditized by NVIDIA, Illumina, and hospital AI-genomics platforms. Severity: high
  • IPO priced into a shaky market window with Nasdaq down about 9.7 percent in late July 2026. Severity: medium
  • Physical health centers beyond Johor Bahru remain unbuilt, limiting the one differentiated asset. Severity: medium
  • No pre-IPO institutional funding found, implying limited capital cushion to survive slow commercialization. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Prenetics / CircleDNAlosing toNasdaq listed with Watsons retail distribution across Asia since July 2019, vs Powercheck's $1,865 FY2025 revenue
Gleneagles Hong Kong / Longevity.Omicsgaining onLaunched AI genomic health service in January 2026, ahead of Powercheck's unbuilt clinic network
NVIDIA-backed genomics AI / Illumina bioinformaticscontestingCommoditizing the AI interpretation layer Powercheck relies on as core value prop, per June 2026 market report
DNAscent (Queensland / Cambridge)contestingAI-powered sequencing platform for biomarker detection reported active as of the June 2026 market report
Questions people ask
Is Powercheck AI Holdings profitable?
No. Powercheck reported FY2025 revenue of just $1,865, disclosed in its Nasdaq F-1 filing dated May 27, 2026. The company is pre-commercial with no institutional customers named, and its physical health centers in Malaysia remain unbuilt as of the filing date.
Who owns Powercheck AI Holdings?
Powercheck AI Holdings is a British Virgin Islands incorporated holding company with operations based in Johor Bahru, Malaysia. It filed its F-1 registration statement on May 27, 2026 to list on Nasdaq as PCAI. No institutional venture funding history was found; the company appears founder funded.
Could AI replace Powercheck AI Holdings?
Powercheck's core offer is AI interpretation of genomic and palm-screening data, exactly the workflow that larger players are commoditizing. As of June 2026, NVIDIA-backed genomics AI, Illumina bioinformatics, and the DNAscent platform from Queensland and Cambridge already compete in this exact function.
Is Powercheck AI Holdings a safe company to join?
Risk is high. Powercheck disclosed FY2025 revenue of only $1,865 in its May 27, 2026 F-1 filing, has no publicly disclosed employee count, no named institutional customers, and its physical clinics beyond Johor Bahru are still unbuilt as of the filing.
Who is Powercheck AI Holdings' biggest competitor?
Prenetics and its CircleDNA brand are the closest direct competitor, a Nasdaq listed genomics company with a Watsons retail distribution partnership across Asia announced July 29, 2019, giving it consumer reach and scale Powercheck has not yet built.
When is Powercheck AI Holdings' IPO?
Powercheck filed its F-1 with the SEC on May 27, 2026, proposing to sell 3,750,000 ordinary shares at $4.00 to $5.00 per share for a raise of roughly $16.9 million. As of June 15, 2026, the exact pricing and listing date remained undetermined.
Timeline
  • 2026-07-28Nasdaq down about 9.7 percent from highs amid AI investment panic, clouding small cap IPO window
  • 2026-06-15IPO pricing and exact Nasdaq listing date for PCAI still undetermined per data aggregator snapshot
  • 2026-06-04Grand View Research report notes rival AI-genomics launches contemporaneous with Powercheck's filing
  • 2026-05-28Press coverage details Powercheck's $16.9 million Nasdaq IPO filing and product lineup
  • 2026-05-27Powercheck AI Holdings files F-1 registration statement with the SEC for Nasdaq listing as PCAI
  • 2026-05-26TradingView lists proposed terms: 3,750,000 shares at $4.00 to $5.00, up to $18.75 million raise
  • 2026-01Gleneagles Hong Kong launches AI genomic health service with Quantum Life's Longevity.Omics platform
  • 2026-01One Genomics and Kyoto University's CiRA Foundation announce AI-driven genome engineering collaboration
  • 2022-06-07Prenetics launches ColoClear non-invasive stool DNA colorectal screening test
  • 2019-07-29Watsons and Prenetics announce retail health partnership across Asia
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources